ThrombosisPub Date : 2011-01-01Epub Date: 2011-12-25DOI: 10.1155/2011/785459
Hossein Kalanie, Ali Amini Harandi, Shapoor Alidaei, Daryoosh Heidari, Saeed Shahbeigi, Mehdi Ghorbani
{"title":"Venous thrombosis in multiple sclerosis patients after high-dose intravenous methylprednisolone: the preventive effect of enoxaparin.","authors":"Hossein Kalanie, Ali Amini Harandi, Shapoor Alidaei, Daryoosh Heidari, Saeed Shahbeigi, Mehdi Ghorbani","doi":"10.1155/2011/785459","DOIUrl":"https://doi.org/10.1155/2011/785459","url":null,"abstract":"<p><p>Aim. This study was designed to examine the possible role of high-dose intravenous methylprednisolone (IVMP) in the development of venous thrombosis (VT). The cerebral one anecdotally had been reported in patients with relapsing remitting multiple sclerosis (RRMS) in acute attacks and the possible preventive role of enoxaparin. Material and Methods. From a pool of 520 patients, 388 patients with definite RRMS who fulfilled entry characteristics were selected and randomly received either a 5-day course of daily 1 gr IVMP or the aforementioned plus 5 days of daily subcutaneous 40 units of enoxaparin according to a predefined protocol. Results. Mean age, gender ratio, mean relapse rate, and EDSS were similar in both groups of patients (P > 0.05). Finally, 366 patients remained in the study. Of 188 patients treated with IVMP with 855 relapses, 5 developed VT (0.37% per patient per year and 0.58% per each course of IVMP) within 3 to 15 days of starting therapy. None of the 178 patients who experienced 809 relapses who received IVMP plus enoxaparin developed such complications. Conclusion. The study implies that high-dose IVMP in MS exacerbation may increase the risk of VT and prophylactic anticoagulant treatment in this setting is warranted.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"785459"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/785459","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30383694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2011-01-01Epub Date: 2011-09-08DOI: 10.1155/2011/652796
D Schoenbeck, A Nicolle, K Newbegin, J Hanley, A D Loughney
{"title":"The use of a scoring system to guide thromboprophylaxis in a high-risk pregnant population.","authors":"D Schoenbeck, A Nicolle, K Newbegin, J Hanley, A D Loughney","doi":"10.1155/2011/652796","DOIUrl":"https://doi.org/10.1155/2011/652796","url":null,"abstract":"<p><p>Guidelines for thromboprophylaxis in pregnancy are usually based upon clinical observations and expert opinion. For optimal impact, their use must be attended by consistency in the advice given to women. In this observational study, we evaluated the performance of a scoring system, used as a guide for clinicians administering dalteparin to pregnant women at increased risk of venous thromboembolism. The work included 47 women treated with dalteparin prior to adoption of the scoring system and 58 women treated with dalteparin after its adoption. The indication for thromboprophylaxis was recorded in each case together with details of the regimen employed, obstetric, and haematological outcomes. The main outcome measure was to determine whether consistency improved after adoption of the scoring system. We also recorded the occurrence of any new venous thromboembolism, haemorrhage, the use of regional anaesthesia during labour, evidence of allergy, and thrombocytopenia. We found that use of the scoring system improved the consistency of advice and increased the mean duration of thromboprophylaxis. None of the subjects suffered venous thromboembolism after assessment using the scoring system. There was no increase in obstetric or anaesthetic morbidity when dalteparin was given antenatally period and no evidence of heparin-induced thrombocytopenia.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"652796"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/652796","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30253906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2011-01-01Epub Date: 2011-12-28DOI: 10.1155/2011/246410
J Hubbard, W E A Saad, S S Sabri, U C Turba, J F Angle, A W Park, A H Matsumoto
{"title":"Rheolytic Thrombectomy with or without Adjunctive Indwelling Pharmacolysis in Patients Presenting with Acute Pulmonary Embolism Presenting with Right Heart Strain and/or Pulseless Electrical Activity.","authors":"J Hubbard, W E A Saad, S S Sabri, U C Turba, J F Angle, A W Park, A H Matsumoto","doi":"10.1155/2011/246410","DOIUrl":"10.1155/2011/246410","url":null,"abstract":"<p><p>Purpose. To evaluate the safety and efficacy of the Possis rheolytic thrombectomy with or without indwelling catheter-directed pharmacolysis for the treatment of massive pulmonary embolus in patients presenting with right heart strain and/or a pulseless electrical activity (PEA). Materials and Methods. Retrospective review of patients undergoing pulmonary pharmacolysis was performed (07/2004-06/2009). Pre- and posttreatment Miller index scoring weres calculated and compared. Patients were evaluated for tPA doses, ICU stay, hospital stay, and survival by Kaplan-Meier analysis. Results. 11 patients with massive PE were found, with 10/11 presenting with a Miller score of >17 (range: 16-27, mean: 23.2). CTPA and/or echocardiographic evidence of right heart strain was found in 10/11 patients. 3 (27%) patients presented with a PEA event. Two (18%) patients had a contraindication to pharmacolysis and were treated with mechanical thrombectomy alone. The intraprocedural mortality was 9% (n = 1/11). Of the 10 patients who survived the initial treatment, 7 patients underwent standard mechanical thrombectomy initially, while 5 received power pulse spray mechanical thrombectomy. Eight of these 10 patients underwent adjunctive indwelling catheter-directed thrombolysis. The mean catheter-directed infusion duration was 18 hours (range of 12-26 hours). The average intraprocedural, infusion, and total doses of tPA were 7 mg, 19.7 mg, and 26.7 mg, respectively. There was a 91% (10/11) technical success rate. The failure was the single mortality. Average reduction in Miller score was 9.5 or 41% (P = 0.009), obstructive index of 6.4 or 47% (P = 0.03), and perfusion index of 2.7 or 28% (P = 0.05). Average ICU and hospital stay were 7.4 days (range 2-27 days) and 21.3 days (range 6-60 days), respectively. Intent to treat survival was 90% at 6, 12, and 18 months. Conclusion. Rheolytic thrombectomy with or without adjunctive catheter-directed thrombolysis provides a safe and effective method for treatment of acute PE in patients who present with right heart strain and/or a PEA event.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"246410"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30393605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2011-01-01Epub Date: 2011-03-06DOI: 10.1155/2011/938709
John Christian Fox, Kiah Christine Bertoglio
{"title":"Emergency Physician Performed Ultrasound for DVT Evaluation.","authors":"John Christian Fox, Kiah Christine Bertoglio","doi":"10.1155/2011/938709","DOIUrl":"https://doi.org/10.1155/2011/938709","url":null,"abstract":"<p><p>Deep vein thrombosis is a common condition that is often difficult to diagnose and may be lethal when allowed to progress. However, early implementation of treatment substantially improves the disease prognosis. Therefore, care must be taken to both acquire an accurate differential diagnosis for patients with symptoms as well as to screen at-risk asymptomatic individuals. Many diagnostic tools exist to evaluate deep vein thrombosis. Compression ultrasonography is currently the most effective diagnostic tool in the emergency department, shown to be highly accurate at minimal expense. However, limited availability of ultrasound technicians may result in delayed imaging or in a decision not to image low-risk cases. Many studies support emergency physiciansas capable of accurately diagnosing deep vein thrombosis using bedside ultrasound. Further integration of ultrasound into the training of emergency physicians for use in evaluating deep vein thrombosis will improve patient care and cost-effective treatment.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"938709"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/938709","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30253910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2011-01-01Epub Date: 2011-05-15DOI: 10.1155/2011/505373
Serdar Toker, David J Hak, Steven J Morgan
{"title":"Deep vein thrombosis prophylaxis in trauma patients.","authors":"Serdar Toker, David J Hak, Steven J Morgan","doi":"10.1155/2011/505373","DOIUrl":"https://doi.org/10.1155/2011/505373","url":null,"abstract":"<p><p>Deep vein thrombosis (DVT) and pulmonary embolism (PE) are known collectively as venous thromboembolism (VTE). Venous thromboembolic events are common and potentially life-threatening complications following trauma with an incidence of 5 to 63%. DVT prophylaxis is essential in the management of trauma patients. Currently, the optimal VTE prophylaxis strategy for trauma patients is unknown. Traditionally, pelvic and lower extremity fractures, head injury, and prolonged immobilization have been considered risk factors for VTE; however it is unclear which combination of risk factors defines a high-risk group. Modalities available for trauma patient thromboprophylaxis are classified into pharmacologic anticoagulation, mechanical prophylaxis, and inferior vena cava (IVC) filters. The available pharmacologic agents include low-dose heparin (LDH), low molecular weight heparin (LMWH), and factor Xa inhibitors. Mechanical prophylaxis methods include graduated compression stockings (GCSs), pneumatic compression devices (PCDs), and A-V foot pumps. IVCs are traditionally used in high risk patients in whom pharmacological prophylaxis is contraindicated. Both EAST and ACCP guidelines recommend primary use of LMWHs in trauma patients; however there are still controversies regarding the definitive VTE prophylaxis in trauma patients. Large randomized prospective clinical studies would be required to provide level I evidence to define the optimal VTE prophylaxis in trauma patients.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"505373"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/505373","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30254945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2011-01-01Epub Date: 2011-02-15DOI: 10.1155/2011/629383
Gregory Cheng, Crystal Chan, Ying Ting Liu, Yee Fun Choy, Mei Mei Wong, Pui Kwan Ernest Yeung, Ka Ling Ng, Lai Shan Tsang, Raymond S M Wong
{"title":"Incidence of Deep Vein Thrombosis in Hospitalized Chinese Medical Patients and the Impact of DVT Prophylaxis.","authors":"Gregory Cheng, Crystal Chan, Ying Ting Liu, Yee Fun Choy, Mei Mei Wong, Pui Kwan Ernest Yeung, Ka Ling Ng, Lai Shan Tsang, Raymond S M Wong","doi":"10.1155/2011/629383","DOIUrl":"https://doi.org/10.1155/2011/629383","url":null,"abstract":"<p><p>Objective. To evaluate the incidence of deep vein thrombosis in hospitalized Chinese medical patients and the impact of DVT prophylaxis. Methods. All cases of confirmed proximal DVT from 1 January 2005 to 31 December 2008 were reviewed retrospectively to determine the presence of risk factors and whether DVT developed: during hospitalization in medical wards or in case of readmission with a diagnosis of DVT within 14 days of discharge from a recent admission to medical wards. The impact of prophylaxis will be estimated by comparing the annual incidence of proximal DVT among medical patients hospitalized from 2005 to 2007 with that of 2008 (DVT prophylaxis commonly used). Results. From 1 January 2005 to 31 December 2008, 3938 Doppler ultrasound studies were performed for suspected DVT. Proximal DVT was diagnosed in 687 patients. The calculated incidence of proximal DVT among medical patients hospitalized for at least two days was 1.8%, 2%, and 1.7% for the year 2005, 2006, and 2007, respectively. The incidence was 1.1% for 2008 (P < .001). Conclusion. Proximal DVT was substantial in Chinese medical patients, and DVT prophylaxis might reduce such risk.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"629383"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/629383","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30253904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2011-01-01Epub Date: 2011-05-26DOI: 10.1155/2011/828030
Brenton Sanderson, Kerry Hitos, John P Fletcher
{"title":"Venous thromboembolism following colorectal surgery for suspected or confirmed malignancy.","authors":"Brenton Sanderson, Kerry Hitos, John P Fletcher","doi":"10.1155/2011/828030","DOIUrl":"10.1155/2011/828030","url":null,"abstract":"<p><p>Surgery for colorectal cancer conveys a high risk of venous thromboembolism (VTE). The effect of thromboprophylactic regimens of varying duration on the incidence of VTE was assessed in 417 patients undergoing surgery between 2005 and 2009 for colorectal cancer. Low-dose unfractionated heparin (LDUH) was used in 52.7% of patients, low-molecular-weight heparin (LMWH) in 35.3%, and 10.7% received LDUH followed by LMWH. Pharmacological prophylaxis was continued after hospitalisation in 31.6%. Major bleeding occurred in 4% of patients. The 30-day mortality rate was 1.9%. The incidence of symptomatic VTE from hospital admission for surgery to 12 months after was 2.4%. There were no in-hospital VTE events. The majority of events occurred in the three-month period after discharge, but there were VTE events up to 12 months, especially in patients with more advanced cancer and multiple comorbidities.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"828030"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30253908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2011-01-01Epub Date: 2011-07-24DOI: 10.1155/2011/874146
Brady L Stein, Alfred Rademaker, Jerry L Spivak, Alison R Moliterno
{"title":"Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.","authors":"Brady L Stein, Alfred Rademaker, Jerry L Spivak, Alison R Moliterno","doi":"10.1155/2011/874146","DOIUrl":"https://doi.org/10.1155/2011/874146","url":null,"abstract":"<p><p>We previously found that gender influenced the JAK2 V617F allele burden, but it is unknown whether this gender difference in molecular epidemiology influences complications in the myeloproliferative neoplasms (MPNs). Historically, vascular complications represented the most common cause of mortality in polycythemia vera and essential thrombocytosis and contributed to morbidity in primary myelofibrosis. To determine the influence of gender on vascular complications, we retrospectively analyzed associations between gender and vascular complications. Despite their younger age, less prevalent dyslipidemia or smoking history, lower white blood counts, and lower JAK2 V617F allele burden, women had higher rates of abdominal venous thrombosis and comparable rates of all vascular complications. Vascular risk is currently not easily stratified by MPN-disease burden or traditional risk factors. Our analysis contributes to growing literature emphasizing gender differences in the MPN and further supports the important impact of individual and host variation on MPN clinical manifestations, and especially vascular risk.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2011 ","pages":"874146"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/874146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30253909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2010-01-01Epub Date: 2009-10-20DOI: 10.1155/2010/908272
Alex R Hobson, Zeshan Qureshi, Phil Banks, Nicholas Curzen
{"title":"The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses.","authors":"Alex R Hobson, Zeshan Qureshi, Phil Banks, Nicholas Curzen","doi":"10.1155/2010/908272","DOIUrl":"https://doi.org/10.1155/2010/908272","url":null,"abstract":"<p><p>Whilst poor response to clopidogrel is associated with adverse outcomes uncertainty exists as to how (a) response should be assessed and (b) poor responders managed. We utilised VerifyNow P2Y12 and short Thrombelastography (TEG) to assess 900 mg doses in (i) initial poor responders to 600 mg and (ii) in a randomised comparison with 600 mg. Blood was taken before and six hours post clopidogrel in (i) 30 volunteers receiving 600 mg (poor responders received 900 mg > two weeks later) and (ii) 60 patients randomized 1 : 1 to 600 mg or 900 mg doses. Poor response was defined as TEG %Clotting Inhibition (%CIn) or VerifyNow Platelet Response Unit (PRU) reduction <30%. (i) Poor responders to 600 mg had greater PRU reduction (45.0 versus 20.1%, P = 0.03) and greater %CIn (22.9 versus -15.1%, P = 0.01) after 900 mg but (ii) there were no significant differences between the patient groups. Near-patient assessment of response to clopidogrel is feasible and clinically useful. Whilst ineffective on a population basis 900 mg doses increase the effect of clopidogrel in initial poor responders.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":" ","pages":"908272"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2010/908272","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30254943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ThrombosisPub Date : 2010-01-01Epub Date: 2010-12-09DOI: 10.1155/2010/416167
Isis S R Carter, Amanda L Vanden Hoek, Edward L G Pryzdial, Ross T A Macgillivray
{"title":"Thrombin a-chain: activation remnant or allosteric effector?","authors":"Isis S R Carter, Amanda L Vanden Hoek, Edward L G Pryzdial, Ross T A Macgillivray","doi":"10.1155/2010/416167","DOIUrl":"https://doi.org/10.1155/2010/416167","url":null,"abstract":"<p><p>Although prothrombin is one of the most widely studied enzymes in biology, the role of the thrombin A-chain has been neglected in comparison to the other domains. This paper summarizes the current data on the prothrombin catalytic domain A-chain region and the subsequent thrombin A-chain. Attention is given to biochemical characterization of naturally occurring prothrombin A-chain mutations and alanine scanning mutants in this region. While originally considered to be simply an activation remnant with little physiologic function, the thrombin A-chain is now thought to play a role as an allosteric effector in enzymatic reactions and may also be a structural scaffold to stabilize the protease domain.</p>","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":" ","pages":"416167"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2010/416167","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30254941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}